4//SEC Filing
Bernards Rene 4
Accession 0001641172-25-018283
CIK 0001335105other
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 9:33 PM ET
Size
14.1 KB
Accession
0001641172-25-018283
Insider Transaction Report
Form 4
Bernards Rene
Director
Transactions
- Award
Options to Purchase Common Stock
2025-06-30+10,000→ 10,000 totalExercise: $0.91From: 2025-09-30Exp: 2030-06-30→ Common (10,000 underlying) - Award
Options to Purchase Common Stock
2025-06-30+10,662→ 10,662 totalExercise: $0.91From: 2025-06-30Exp: 2030-06-30→ Common (10,662 underlying)
Holdings
- 8,045
Options to Purchase Common Stock
Exercise: $1.21From: 2025-03-31Exp: 2030-03-31→ Common (8,045 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 5,304
Options to Purchase Common Stock
Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (5,304 underlying) - 4,166
Options to Purchase Common Stock
Exercise: $2.33From: 2025-01-20Exp: 2030-01-20→ Common (4,166 underlying) - 4,149
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,149 underlying)
Footnotes (2)
- [F1]Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.
- [F2]Effective June 30, 2025 the reporting person was granted stock options to purchase an aggregate of 10,662 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.
Documents
Issuer
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
CIK 0001335105
Entity typeother
Related Parties
1- filerCIK 0001939159
Filing Metadata
- Form type
- 4
- Filed
- Jul 7, 8:00 PM ET
- Accepted
- Jul 8, 9:33 PM ET
- Size
- 14.1 KB